Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Efalizumab · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Efalizumab | DRUG | - |
Inclusion Criteria: 1. Signed informed consent 2. Plaque psoriasis covering ³10% of total BSA 3. Diagnosis of plaque psoriasis for at least 6 months 4. A minimum PASI score of 12.0 at screening 5. In the opinion of the investigator, candidate for systemic therapy for psoriasis 6. Body weight of £12...
Efalizumab is used for the treatment of moderate to severe psoriasis, a chronic skin condition. It is being developed as a small molecule therapy for this dermatological indication. The drug is currently in Phase 3 clinical development, meaning it is still investigational and has not yet been approved for commercial use.
Efalizumab is being developed by Merck KGaA, a multinational pharmaceutical company. The company's stock is traded under the ticker symbol MKGAF. Merck KGaA is conducting clinical trials to evaluate the safety and efficacy of Efalizumab for the treatment of moderate to severe psoriasis.
Efalizumab is in Phase 3 clinical development. This is the final stage of testing before a potential regulatory submission. The drug is being studied for the treatment of moderate to severe psoriasis. As of now, Efalizumab is still investigational and has not received approval from regulatory authorities.
Efalizumab has one completed Phase 3 clinical trial registered under the identifier NCT00442650. The trial was titled "Efalizumab for Treatment of Patients With Moderate to Severe Psoriasis" and was conducted in Switzerland. The study enrolled adult patients aged 18 years and older with moderate to severe psoriasis.
Efalizumab is not FDA approved. It is an investigational drug currently in Phase 3 clinical development for the treatment of moderate to severe psoriasis. The drug has completed one clinical trial, but it has not yet been submitted for regulatory approval or authorized for use in any market.